Delving into the Latest Updates on Beijing Zehui Chenxing Biotechnology Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Respiratory Diseases

Skin and Musculoskeletal Diseases

Stem cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Stem cell therapy	1

Primary purpose: To evaluate the preliminary effectiveness of CAStem cell injection in the treatment of AE-ILD. Secondary purpose: To evaluate the safety of CAStem cell injection in the treatment of AE-ILD. Exploratory purpose: To explore the potential relationship between the changes in peripheral blood biomarker concentrations before and after CAStem cell injection and the efficacy.

Start Date-

Sponsor / Collaborator

Beijing Zehui Chenxing Biotechnology Co., Ltd.

CTR20221454 / RecruitingPhase 2

CAStem细胞注射液治疗急性呼吸窘迫综合征的有效性和安全性研究

[Translation] Study on the efficacy and safety of CAStem cell injection in the treatment of acute respiratory distress syndrome

主要目的：评价CAStem细胞注射液治疗急性呼吸窘迫综合征（ARDS）的初步有效性。次要目的：评价CAStem细胞注射液治疗ARDS的安全性和耐受性。探索性目的：探索CAStem细胞注射液治疗前后外周血和肺泡灌洗液生物标志物变化以及与疗效之间的潜在关系。

[Translation]

Primary objective: To evaluate the preliminary efficacy of CAStem cell injection in the treatment of acute respiratory distress syndrome (ARDS). Secondary objective: To evaluate the safety and tolerability of CAStem cell injection in the treatment of ARDS. Exploratory objective: To explore the changes in biomarkers in peripheral blood and bronchoalveolar lavage fluid before and after CAStem cell injection treatment and their potential relationship with efficacy.

Start Date10 Dec 2022

Sponsor / Collaborator

Beijing Zehui Chenxing Biotechnology Co., Ltd.

CTR20220157 / RecruitingPhase 1/2

评估CAStem细胞注射液经膝关节腔内注射治疗中国半月板损伤受试者的安全性、耐受性和初步疗效的临床试验

[Translation] A clinical trial to evaluate the safety, tolerability and preliminary efficacy of CAStem cell injection via intra-articular injection in the treatment of meniscus injuries in Chinese subjects

主要目的是评价CAStem细胞注射液用于半月板损伤的受试者经膝关节腔内注射给药后的安全性和耐受性。次要目的是评价CAStem细胞注射液用于半月板损伤受试者经膝关节腔内注射给药后的初步疗效。

[Translation]

The primary objective is to evaluate the safety and tolerability of CAStem cell injection in subjects with meniscus injury after intra-articular injection in the knee. The secondary objective is to evaluate the preliminary efficacy of CAStem cell injection in subjects with meniscus injury after intra-articular injection in the knee.

Start Date04 Mar 2022

Sponsor / Collaborator

Institute of Zoology Chinese Academy of Science

[+1]

100 Clinical Results associated with Beijing Zehui Chenxing Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Zehui Chenxing Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Zehui Chenxing Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Zehui Chenxing Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Other

Login to view more data